摘要
目的:探讨重症革兰氏阳性菌感染患者应用替考拉宁与万古霉素治疗效果对比情况。方法:选择革兰氏阳性菌感染引发的感染患者100例,均为某院2015年10月～2017年10月收治,随机分组,就应用万古霉素治疗(对照组,n=50)与应用替考拉宁治疗(观察组,n=50)效果展开对比。结果:观察组选取的重症革兰阳性菌感染患者总有效率经统计为90%,明显高于对照组72%(P<0.05);观察组患者病原菌总清除率经统计为92%,明显高于对照组72%(P<0.05);观察组不良反应率为8%,明显低于对照组22%,具有统计学差异(P<0.05)。结论:针对临床收治的重症革兰氏阳性菌感染病例,应用万古霉素与替考拉宁治疗,均可起到一定作用,但替考拉宁临床效果更为显著,且有较高的病原菌清除率,在安全性上也居更高水平,具有更为重要的应用价值。
Objective To investigate the treatment effect between teicoplanin and vancomycin on the patients with severe gram-positive bacterial infection. Methods： 100 cases of patients withsevere gram-positive bacterial infection admitted in a hospital from October 2015 to October 2017 were randomly grouped, com-pared the efficacy of vancomycin （control group, n =50） with that of tacolamine （observation group, n =50）. Results： The total effective rate of patients with severe gram-positive bacterial infection in the observation group was 90%, significantly higher than that in the control group （ P 〈0.05）.The total clearance rate of pathogenic bacteria in the observation group was 92%, significantly higher than that in the control group （ P 〈0.05）.The adverse reaction rate of the observation group was 8%, significantly lower than that of the control group by 22%, with a statistically significant difference （ P 〈0.05）. Conclusion： Both vancomycin and teicoplanin can play roles in the treatment of severe gram-positive bacterial infection.However, the clinical effect of teicoplanin is more significant, and it has a higher rate of pathogen clearance, a higher level of safety and more important application value.
作者
李芳芳
朱坚胜
Li Fangfang(Department of Infectious Disease,Taizhou Hospital Affiliated to Wenzhou MedicalUniversity,Wenzhou 317000)
出处
《数理医药学杂志》
2018年第11期1670-1672,共3页
Journal of Mathematical Medicine
